ScienceDirect® Home Skip Main Navigation Links
You have guest access to ScienceDirect. Find out more.
 
Home
Browse
My Settings
Alerts
Help
 Quick Search
 Search tips (Opens new window)
    Clear all fields    
 
Font Size: Decrease Font Size  Increase Font Size
 Abstract - selected
Article
Purchase PDF (311 K)

Article Toolbox
 
 
 
Related Articles in ScienceDirect
View More Related Articles
 
View Record in Scopus
 
doi:10.1016/j.bmc.2007.02.029    
How to Cite or Link Using DOI (Opens New Window)

Copyright © 2007 Elsevier Ltd All rights reserved.

Design, synthesis, and biological evaluation of substituted-N-(thieno[2,3-b]pyridin-3-yl)-guanidines, N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidines, and N-(1H-indol-3-yl)-guanidinesstar, open

Purchase the full-text article



References and further reading may be available for this article. To view references and further reading you must purchase this article.

Rajesh H. Bahekara, Mukul R. JainCorresponding Author Contact Information, a, E-mail The Corresponding Author, Ashish Goela, Dipam N. Patela, Vijay M. Prajapatia, Arun A. Guptaa, Pradip A. Jadava and Pankaj R. Patela

aZydus Research Centre, Cadila Healthcare Ltd., Sarkhej-Bavala N.H. 8A, Moraiya, Ahmedabad 382210, India


Received 28 December 2006; 
revised 13 February 2007; 
accepted 14 February 2007. 
Available online 16 February 2007.

Abstract

Sulfonylureas stimulate insulin secretion independent of the blood glucose concentration and therefore cause hypoglycemia in type 2 diabetic patients. Over the last years, a number of aryl-imidazoline derivatives have been identified that stimulate insulin secretion in a glucose-dependent manner. In the present study, we have developed three series of substituted N-(thieno[2,3-b]pyridin-3-yl)-guanidine (2al), N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3al), and N-(1H-indol-3-yl)-guanidine (4al) as new class of antidiabetic agents. In vitro glucose-dependent insulinotropic activity of test compounds 2al, 3al, and 4al was evaluated using RIN5F (Rat Insulinoma cell) based assay. All the test compounds showed concentration-dependent insulin secretion, only in presence of glucose load (16.7 mmol). Some of the test compounds (2c, 3c, and 4c) from each series were found to be equipotent to BL 11282 (standard aryl-imidazoline), which indicated that the guanidine group acts as a bioisostere of imidazoline ring system.

Graphical abstract

New class of substituted hetero-aryl guanidine derivatives were prepared as BL 11282 analog and screened in vitro for glucose-dependent insulinotropic activity.

Full-size image

Keywords: Guanidine; Pyrrolo[2,3-b]pyridine; Thieno[2,3-b]pyridine; Indole; Type 2 diabetes; Insulinotropic; Antidiabetic

Article Outline

1. Introduction
2. Chemistry
3. Results and discussion
3.1. In vitro insulin secretion assay results
4. Conclusions
5. Experimental
5.1. Chemistry
5.2. Experimental details
5.2.1. General method for the synthesis of N-(2,5-disubstituted-thieno[2,3-b]pyridin-3-yl)-guanidine (2al; Scheme 1)
5.2.1.1. Synthesis of bis-Boc-N-(thieno[2,3-b]pyridin-3-yl)-guanidine (6a)
5.2.1.2. Bis-Boc-N-(5-chloro-thieno[2,3-b]pyridin-3-yl)-guanidine (6b)
5.2.1.3. Bis-Boc-N-(5-chloro-2-methyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6c)
5.2.1.4. Bis-Boc-N-(2-methyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6d)
5.2.1.5. Bis-Boc-N-(2-phenyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6e)
5.2.1.6. Bis-Boc-N-(5-chloro-2-phenyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6f)
5.2.1.7. Bis-Boc-N-(2-cyclohexyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6g)
5.2.1.8. Bis-Boc-N-(5-chloro-2-cyclohexyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6h)
5.2.1.9. Bis-Boc-N-(2-ethyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6i)
5.2.1.10. Bis-Boc-N-(5-chloro-2-ethyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6j)
5.2.1.11. Bis-Boc-N-(2-benzyl-thieno[2,3-b]pyridin-3-yl)-guanidine (6k)
5.2.1.12. Bis-Boc-N-(2-benzyl-5-chloro-thieno[2,3-b]pyridin-3-yl)-guanidine (6l)
5.2.1.13. Synthesis of N-(thieno[2,3-b]pyridin-3-yl)-guanidine (2a)
5.2.1.14. N-(5-Chloro-thieno[2,3-b]pyridin-3-yl)-guanidine (2b)
5.2.1.15. N-(5-Chloro-2-methyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2c)
5.2.1.16. N-(2-Methyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2d)
5.2.1.17. N-(2-Phenyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2e)
5.2.1.18. N-(5-Chloro-2-phenyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2f)
5.2.1.19. N-(2-Cyclohexyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2g)
5.2.1.20. N-(5-Chloro-2-cyclohexyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2h)
5.2.1.21. N-(2-Ethyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2i)
5.2.1.22. N-(5-Chloro-2-ethyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2j)
5.2.1.23. N-(2-Benzyl-thieno[2,3-b]pyridin-3-yl)-guanidine (2k)
5.2.1.24. N-(2-Benzyl-5-chloro-thieno[2,3-b]pyridin-3-yl)-guanidine (2l)
5.2.2. General method for the synthesis of N-(2,5-disubstituted-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3al; Scheme 2)
5.2.2.1. Synthesis of 3-nitroso-1H-pyrrolo[2,3-b]pyridine (8a)
5.2.2.2. 5-Chloro-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8b)
5.2.2.3. 5-Chloro-2-methyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8c)
5.2.2.4. 2-Methyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8d)
5.2.2.5. 3-Nitroso-2-phenyl-1H-pyrrolo[2,3-b]pyridine (8e)
5.2.2.6. 5-Chloro-3-nitroso-2-phenyl-1H-pyrrolo[2,3-b]pyridine (8f)
5.2.2.7. 2-Cyclohexyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8g)
5.2.2.8. 5-Chloro-2-cyclohexyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8h)
5.2.2.9. 2-Ethyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8i)
5.2.2.10. 5-Chloro-2-ethyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8j)
5.2.2.11. 2-Benzyl-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8k)
5.2.2.12. 2-Benzyl-5-chloro-3-nitroso-1H-pyrrolo[2,3-b]pyridine (8l)
5.2.2.13. Synthesis of 3-amino-1H-pyrrolo[2,3-b]pyridine (9a)
5.2.2.14. 5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9b)
5.2.2.15. 5-Chloro-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9c)
5.2.2.16. 2-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9d)
5.2.2.17. 2-Phenyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9e)
5.2.2.18. 5-Chloro-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9f)
5.2.2.19. 2-Cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9g)
5.2.2.20. 5-Chloro-2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9h)
5.2.2.21. 2-Ethyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9i)
5.2.2.22. 5-Chloro-2-ethyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9j)
5.2.2.23. 2-Benzyl-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9k)
5.2.2.24. 2-Benzyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylamine (9l)
5.2.2.25. Synthesis of bis-Boc-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10a)
5.2.2.26. Bis-Boc-N-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10b)
5.2.2.27. Bis-Boc-N-(5-chloro-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10c)
5.2.2.28. Bis-Boc-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10d)
5.2.2.29. Bis-Boc-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10e)
5.2.2.30. Bis-Boc-N-(5-chloro-2-Phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10f)
5.2.2.31. Bis-Boc-N–(2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10g)
5.2.2.32. Bis-Boc-N-(5-chloro-2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10h)
5.2.2.33. Bis-Boc-N-(2-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10i)
5.2.2.34. Bis-Boc-N-(5-chloro-2-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10j)
5.2.2.35. Bis-Boc-N-(2-benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10k)
5.2.2.36. Bis-Boc-N-(2-benzyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (10l)
5.2.2.37. Synthesis of N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3a)
5.2.2.38. N-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3b)
5.2.2.39. N-(5-Chloro-2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3c)
5.2.2.40. N-(2-Methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3d)
5.2.2.41. N-(2-Phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3e)
5.2.2.42. N-(5-Chloro-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3f)
5.2.2.43. N-(2-Cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3g)
5.2.2.44. N-(5-Chloro-2-cyclohexyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3h)
5.2.2.45. N-(2-Ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3i)
5.2.2.46. N-(5-Chloro-2-ethyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3j)
5.2.2.47. N-(2-Benzyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3k)
5.2.2.48. N-(2-Benzyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-guanidine (3l)
5.2.3. General method for the synthesis of N-(2,5-disubstituted-1H-indol-3-yl)-guanidine (4al; Scheme 3)
5.2.3.1. Synthesis of 3-nitro-1H-indole (12a)
5.2.3.2. 5-Chloro-3-nitro-1H-indole (12b)
5.2.3.3. 5-Chloro-2-methyl-3-nitro-1H-indole (12c)
5.2.3.4. 2-Methyl-3-nitro-1H-indole (12d)
5.2.3.5. 3-Nitro-2-phenyl-1H-indole (12e)
5.2.3.6. 5-Chloro-3-nitro-2-phenyl-1H-indole (12f)
5.2.3.7. 2-Cyclohexyl-3-nitro-1H-indole (12g)
5.2.3.8. 5-Chloro-2-cyclohexyl-3-nitro-1H-indole (12h)
5.2.3.9. 2-Ethyl-3-nitro-1H-indole (12i)
5.2.3.10. 5-Chloro-2-ethyl-3-nitro-1H-indole (12j)
5.2.3.11. 2-Benzyl-3-nitro-1H-indole (12k)
5.2.3.12. 2-Benzyl-5-chloro-3-nitro-1H–indole (12l)
5.2.3.13. Synthesis of 3-amino-1H-indole (13a)
5.2.3.14. 5-Chloro-1H-indol-3-ylamine (13b)
5.2.3.15. 5-Chloro-2-methyl-1H-indol-3-ylamine (13c)
5.2.3.16. 2-Methyl-1H-indol-3-ylamine (13d)
5.2.3.17. 2-Phenyl-1H-indol-3-ylamine (13e)
5.2.3.18. 5-Chloro-2-phenyl-1H-indol-3-ylamine (13f)
5.2.3.19. 2-Cyclohexyl-1H-indol-3-ylamine (13g)
5.2.3.20. 5-Chloro-2-cyclohexyl-1H-indol-3-ylamine (13h)
5.2.3.21. 2-Ethyl-1H-indol-3-ylamine (13i)
5.2.3.22. 5-Chloro-2-ethyl-1H-indol-3-ylamine (13j)
5.2.3.23. 2-Benzyl-1H-indol-3-ylamine (13k)
5.2.3.24. 2-Benzyl-5-chloro-1H-indol-3-ylamine (13l)
5.2.3.25. Synthesis of bis-Boc-N-(1H-indol-3-yl)-guanidine (14a)
5.2.3.26. Bis-Boc-N-(5-chloro-1H-indol-3-yl)-guanidine (14b)
5.2.3.27. Bis-Boc-N-(5-chloro-2-methyl-1H-indol-3-yl)-guanidine (14c)
5.2.3.28. Bis-Boc-N-(2-methyl-1H-indol-3-yl)-guanidine (14d)
5.2.3.29. Bis-Boc-N-(2-phenyl-1H-indol-3-yl)-guanidine (14e)
5.2.3.30. Bis-Boc-N-(5-chloro-2-Methyl-1H-indol-3-yl)-guanidine (14f)
5.2.3.31. Bis-Boc-N-(2-cyclohexyl-1H-indol-3-yl)-guanidine (14g)
5.2.3.32. Bis-Boc-N-(5-chloro-2-cyclohexyl-1H-indol-3-yl)-guanidine (14h)
5.2.3.33. Bis-Boc-N-(2-ethyl-1H-indol-3-yl)-guanidine (14i)
5.2.3.34. Bis-Boc-N-(5-chloro-2-ethyl-1H-indol-3-yl)-guanidine (14j)
5.2.3.35. Bis-Boc-N-(2-benzyl-1H-indol-3-yl)-guanidine (14k)
5.2.3.36. Bis-Boc-N-(5-chloro-2-benzyl-1H-indol-3-yl)-guanidine (14l)
5.2.3.37. Synthesis of N-(1H-Indol-3-yl)-guanidine (4a)
5.2.3.38. N-(5-Chloro-1H-indol-3-yl)-guanidine (4b)
5.2.3.39. N-(5-Chloro-2-methyl-1H-indol-3-yl)-guanidine (4c)
5.2.3.40. N-(2-Methyl-1H-indol-3-yl)-guanidine (4d)
5.2.3.41. N-(2-Phenyl-1H-indol-3-yl)-guanidine (4e)
5.2.3.42. N-(5-Chloro-2-phenyl-1H-indol-3-yl)-guanidine (4f)
5.2.3.43. N-(2-Cyclohexyl-1H-indol-3-yl)-guanidine (4g)
5.2.3.44. N-(5-Chloro-2-cyclohexyl-1H-indoyl-3-yl)-guanidine (4h)
5.2.3.45. N-(2-Ethyl-1H-indol-3-yl)-guanidine (4i)
5.2.3.46. N-(5-Chloro-2-ethyl-1H-indol-3-yl)-guanidine (4j)
5.2.3.47. N-(2-Benzyl-1H-indol-3-yl)-guanidine (4k)
5.2.3.48. N-(2-Benzyl-5-chloro-1H-indol-3-yl)-guanidine (4l)
5.3. In vitro glucose-dependent insulin secretion (RIN5F cell assay screening protocol)
Acknowledgements
References




star, openZRC communication No. 189.


Corresponding Author Contact InformationCorresponding author. Tel.: +91 2717 250801; fax: +91 2717 250606.

 
Home
Browse
My Settings
Alerts
Help
Elsevier.com (Opens new window)
About ScienceDirect  |  Contact Us  |  Information for Advertisers  |  Terms & Conditions  |  Privacy Policy